This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott's (ABT) New FDA Approval to Improve Patient Outcome
by Zacks Equity Research
Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.
Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update
by Zacks Equity Research
Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.
Why Abbott (ABT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $111.80, marking a +0.26% move from the previous day.
The Zacks Analyst Blog Highlights Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical.
by Zacks Equity Research
Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical are part of the Zacks top Analyst Blog.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Top Analyst Reports for Pfizer, Abbott Laboratories & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP).
Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $111.36, marking a -1.58% move from the previous day.
Abbott's (ABT) New Launch to Boost Blood Donation Experience
by Zacks Equity Research
Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $112.33, moving +1.38% from the previous trading session.
Abbott (ABT) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $109.58, marking a -0.19% move from the previous day.
Abbott (ABT) to Upgrade PHCs Across India With New Pact
by Zacks Equity Research
Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $108.57, marking a +0.36% move from the previous day.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott's (ABT) FreeStyle Libre 3 Integrates With AID System
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 integration with mylife Loop solutions will help build a smart, automated process to deliver insulin based on real-time glucose data.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business and product launches.
Abbott's (ABT) Eterna SCS System Receives FDA's Approval
by Zacks Equity Research
Abbott's (ABT) Eterna SCS technology shows 23% more pain reduction compared with traditional waveform technology approaches.
Abbott (ABT) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $106.59, marking a -0.3% move from the previous day.
Top Research Reports for Berkshire Hathaway, Exxon Mobil & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BR.B), Exxon Mobil Corporation (XOM) and Pfizer Inc. (PFE).
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $111.53, marking a +1.86% move from the previous day.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $104.81, moving +0.91% from the previous trading session.